Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes  : Episode 6

Management of GI Toxicities in Osimertinib and other EGFR Inhibitors

February 5, 2025

Opinion

Video

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on preventive measures and comparisons with GI management strategies for other EGFR inhibitors.

EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC

EP: 2.Patient Guidance and Education of EGFR Inhibitor Therapies

EP: 3.Strategies to Managing Cardiotoxic AEs with Osimertinib

EP: 4.Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients

EP: 5.Strategies of Dose Modifications of Osimertinib and Other EGFR Inhibitors

Now Viewing

EP: 6.Management of GI Toxicities in Osimertinib and other EGFR Inhibitors

EP: 7.Importance of Multidisciplinary Team in Managing AEs of EGFR Inhibitors

EP: 8.Comparison of Safety Profiles of EGFR Inhibitors

EP: 9.Jason’s Journey with ALK+ Metatstatic NSCLC

EP: 10.Patient Education and Guidance on Lorlatinib and Other ALK Inhibitors

EP: 11.Management of Neurotox AEs with Lorlatinib

EP: 12.Management of Hyperlipidemia and Weight Gain with Lorlatinib

EP: 13.Management of GI AEs with ALK Inhibitors

EP: 14.Dose Modifications When Managing Side Effects with ALK Inhibitors

EP: 15.Role of Multidisciplinary Strategies in care of ALK+ NSCLC Patients

EP: 16.Patient Factors in Treatment Selection of ALK Inhibitors

Video content above is prompted by the following:

How do you handle gastrointestinal side effects in patients taking osimertinib?
Do you provide any preventive measures for patients, and how does this compare to managing GI issues from other EGFR inhibitors?

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!